Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowJust a week after announcing that it has started dosing human patients with a potential treatment for COVID-19, Eli Lilly and Co. said June 8 that its Chinese partner, Junshi Biosciences has dosed the first volunteer with another experimental medicine for the disease.
The Indianapolis drugmaker also said it expects to begin dosing patients in a complementary clinical study in the U.S. in the coming days. Under the partnership agreement, Junshi Biosciences is leading development of the antibody in China, and Lilly has exclusive rights in the rest of the world.
Both early-stage studies aim to evaluate the safety and tolerability of the drug, known as JS016, in healthy participants who have not been diagnosed with COVID-19.
Lilly said on June 1 that it had begun dosing patients with LY-CoV555 at major medical centers in the United States, including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles.
Lilly scientists have developed the treatment over the past three months using an antibody identified by Vancouver-based AbCellera Biologics Inc. from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.•
Please enable JavaScript to view this content.